Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event is scheduled for September 23, 2026, at 9 a.m. EDT and will be webcast live. The summit brings together experts to discuss emerging mechanisms in neuropsychiatry, and Helus Pharma's participation signals the growing recognition of its NSA platform.
NSAs are synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. This mechanism could offer a new approach for treating depression, anxiety, and other mental health conditions where current therapies fall short. Helus Pharma aims to address the large unmet need in mental health through its proprietary NSAs, which have shown class-leading data.
The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation is intended to expedite the development and review of drugs that may demonstrate substantial improvement over existing therapies. A second candidate, HLP004, is in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
For investors, the TD Cowen summit provides a platform for management to discuss the company's clinical progress and strategic vision. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) operates in Canada, the United States, the United Kingdom, and Ireland, positioning it within key markets for mental health therapeutics. The company was founded in 2019 and is the commercial operating name of Cybin Inc. Its mission is to help minds heal by developing innovative treatments that aim to provide durable improvements in mental health.
To learn more about Helus Pharma, visit www.helus.com. The full press release can be viewed at https://nnw.fm/8dLEZ.
The announcement was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. These services aim to help companies reach a wide audience of investors, influencers, consumers, journalists, and the general public.
The implications of Helus Pharma's participation in the TD Cowen summit extend beyond a single event. It highlights the increasing interest in novel mechanisms for treating mental health disorders, which affect millions worldwide. If successful, NSAs could provide new options for patients who do not respond adequately to existing treatments. For the pharmaceutical industry, this represents a potential paradigm shift in neuropsychiatry, with serotonin pathway modulation at the forefront. Investors and industry watchers will be keen to hear updates on HLP003 and HLP004, as well as the broader NSA pipeline.
